Stephen Gwaltney, Ph.D.

Dr. Steve Gwaltney is an experienced drug discovery and development professional with a proven track record of performance, including delivery of three marketed drugs.  Dr. Gwaltney currently serves as Vice President of Chemistry of ApoGen Biotechnologies (an Accelerator Life Science Partners’ portfolio company) and chemistry consultant to Rodeo Therapeutics (an Accelerator Life Science Partners’ portfolio company – acquired by Amgen Inc).  Prior to these roles, Dr. Gwaltney founded Chrysalis Therapeutics serving as President and Chief Scientific Officer.  He served as Vice President of Chemistry at Global Blood Therapeutics and as Director of Chemistry at Takeda San Diego (formerly Syrrx, Inc.).  Dr. Gwaltney has served on the board of the San Diego Section of the American Chemical Society and on the San Diego Research Committee of the American Diabetes Association. Dr. Gwaltney has co-authored more than 25 peer-reviewed scientific articles and is co-inventor on 45 issued U.S. patents.

Dr. Gwaltney received his B.Sc. in Chemistry from Indiana University Bloomington and Ph.D. in Chemistry from University of California, Irvine.